WO1994006921B1 - Recombinant retroviral vector against felv and/or fiv - Google Patents
Recombinant retroviral vector against felv and/or fivInfo
- Publication number
- WO1994006921B1 WO1994006921B1 PCT/US1993/009070 US9309070W WO9406921B1 WO 1994006921 B1 WO1994006921 B1 WO 1994006921B1 US 9309070 W US9309070 W US 9309070W WO 9406921 B1 WO9406921 B1 WO 9406921B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector construct
- virus
- feline
- directs
- expression
- Prior art date
Links
- 230000001177 retroviral effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract 13
- 102000036639 antigens Human genes 0.000 claims abstract 13
- 108091007433 antigens Proteins 0.000 claims abstract 13
- 241000714165 Feline leukemia virus Species 0.000 claims abstract 10
- 230000014509 gene expression Effects 0.000 claims abstract 10
- 230000002163 immunogen Effects 0.000 claims abstract 10
- 241000713800 Feline immunodeficiency virus Species 0.000 claims abstract 8
- 230000009385 viral infection Effects 0.000 claims abstract 6
- 241000282324 Felis Species 0.000 claims abstract 3
- 241000700605 Viruses Species 0.000 claims 7
- 241001430294 unidentified retrovirus Species 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000709661 Enterovirus Species 0.000 claims 2
- 241000991587 Enterovirus C Species 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 2
- 201000005505 Measles Diseases 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 241000125945 Protoparvovirus Species 0.000 claims 2
- 241000710960 Sindbis virus Species 0.000 claims 2
- 230000004186 co-expression Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims 1
- 241000701915 Feline panleukopenia virus Species 0.000 claims 1
- 241000711798 Rabies lyssavirus Species 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
Abstract
The present invention provides methods for treating or preventing feline leukemia virus infections comprising, administering to a feline a vector construct which directs the expression of at least one immunogenic portion of a feline leukemia virus antigen, such that a cellular immune response is generated. Also provided are methods and vector constructs for treating or preventing feline immunodeficiency virus infections, either separately or in combination with the above-described methods for treating or preventing feline leukemia virus infections.
Claims
45
AMENDED CLAIMS
[received by the International Bureau on 14 April 1994 (14.04.94); original claims 1-19 replaced by amended claims 1-19 (3 pages)]
1. A vector construct which directs the expression of at least one immunogenic portion of a feline leukemia virus antigen for use in the manufacture of a medicament for treating or preventing feline leukemia virus infections.
2. The vector construct of claim 1 wherein said vector construct directs the expression of an antigen selected from the group consisting of plδgαg, pYlgαg, p21gαg, plOgαg, pl4pol, pSOpol, p46pol, gpl env, and pl5env.
3. The vector construct of claim 1 wherein said vector construct directs the expression of gp85env.
4. A vector construct which directs the expression of at least one immunogenic portion of a feline immunodeficiency virus antigen for use in the manufacture of a medicament for treating or preventing feline immunodeficiency virus infections.
5. The vector construct of claim 4 wherein said vector construct directs the expression of an antigen selected from the group consisting of pl5gαg, p24gαg, plOgαg, pl3pol, p62pol, pl5pol and p36pol.
6. The vector construct of claim 4 wherein said vector construct directs the expression of gpόδenv, gp27env and rev.
1. A vector construct which directs the co-expression of at least one immunogenic portion of a feline leukemia virus antigen, and at least one immunogenic portion of a feline immunodeficiency virus antigen for use in the manufacture of a medicament for treating or preventing feline leukemia virus and feline immunodeficiency virus infections.
8. The vector construct of claim 7 wherein said vector construct also directs the expression of an immunogenic portion of a feline virus selected from the group consisting of feline panleukopenia virus, feline calicivinis, the rabies virus, and feline herpesvirus.
46
9. The vector construct of claims 1, 4, or 7 wherein said vector construct is carried by a recombinant retrovirus.
10. The vector construct of claims 1, 4 or 7 wherein said vector construct is carried by a recombinant virus selected from the group consisting of poliovirus, rhinovirus, pox virus, influenza virus, adenovirus, parvovirus, herpes virus, SV40, HIV, measles and Sindbis virus.
11. A vector construct which directs the co-expression of at least one immunogenic portion of a feline immunodeficiency virus antigen, and at least one immunogenic portion of a feline leukemia virus antigen.
12. The vector construct of claim 11 wherein said feline leukemia virus antigen is gp85env, and said feline immunodeficiency virus antigen is gp68e«v, gp21env, and rev.
13. A recombinant retrovirus carrying a vector construct according to claims 11 or 12.
14. A recombinant retrovirus carrying a vector construct which directs the expression of at least one immunogenic portion of a feline leukemia virus antigen.
15. A recombinant retrovirus carrying a vector construct which directs the expression of at least one immunogenic portion of a feline immunodeficiency virus antigen.
16. A recombinant virus carrying a vector construct according to claims 11 or 12, said virus selected from the group consisting of poliovirus, rhinovirus, pox virus, influenza virus, adenovirus, parvovirus, herpes virus, SV40, HIV, measles and Sindbis virus.
17. Target cells infected with the recombinant retrovirus of claims 13, 14 or 15.
18. A pharmaceutical composition comprising the recombinant retrovirus of claims 13, 14 or 15, in combination with a pharmaceutically acceptable carrier or diluent.
47
19. A pharmaceutical composition comprising the recombinant virus of claim 16, in combination with a pharmaceutically acceptable carrier or diluent.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU51382/93A AU5138293A (en) | 1992-09-21 | 1993-09-21 | Recombinant retroviral vector against felv and/or fiv |
| JP6508444A JPH08501452A (en) | 1992-09-21 | 1993-09-21 | Recombinant retrovirus vector for FELV and / or FIV |
| EP93922364A EP0662139A1 (en) | 1992-09-21 | 1993-09-21 | Recombinant retroviral vector against felv and/or fiv |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94835892A | 1992-09-21 | 1992-09-21 | |
| US07/948,358 | 1992-09-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994006921A1 WO1994006921A1 (en) | 1994-03-31 |
| WO1994006921B1 true WO1994006921B1 (en) | 1994-05-11 |
Family
ID=25487709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1993/009070 WO1994006921A1 (en) | 1992-09-21 | 1993-09-21 | Recombinant retroviral vector against felv and/or fiv |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0662139A1 (en) |
| JP (1) | JPH08501452A (en) |
| AU (1) | AU5138293A (en) |
| CA (1) | CA2142325A1 (en) |
| WO (1) | WO1994006921A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1679377A1 (en) * | 1994-04-29 | 2006-07-12 | Pharmacia & Upjohn Company LLC | Feline immunodeficiency virus vaccine |
| US5820869A (en) * | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
| US6300118B1 (en) | 1995-06-07 | 2001-10-09 | American Home Products Corporation | Plasmids comprising a genetically altered feline immunodeficiency virus genome |
| FR2751223B1 (en) * | 1996-07-19 | 1998-12-04 | Rhone Merieux | FELIN POLYNUCLEOTIDE VACCINE FORMULA |
| EP0973538B1 (en) | 1997-04-10 | 2008-03-12 | University of Southern California | Modified proteins which bind extracellular matrix components |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10399032I1 (en) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Recombinant viruses. |
| ATE130631T1 (en) * | 1988-08-08 | 1995-12-15 | Upjohn Co | METHOD FOR ISOLATION FOR THYMIDINE KINASE FROM DNA CODING FOR HERPES VIRUS. |
| GB8901778D0 (en) * | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
-
1993
- 1993-09-21 CA CA002142325A patent/CA2142325A1/en not_active Abandoned
- 1993-09-21 WO PCT/US1993/009070 patent/WO1994006921A1/en not_active Application Discontinuation
- 1993-09-21 EP EP93922364A patent/EP0662139A1/en not_active Withdrawn
- 1993-09-21 AU AU51382/93A patent/AU5138293A/en not_active Abandoned
- 1993-09-21 JP JP6508444A patent/JPH08501452A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2224257A1 (en) | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection | |
| CA2117303A1 (en) | Anti-Cancer Immunotherapeutic Vector Constructs | |
| US5840843A (en) | Synthetic polypeptides as inhibitors of HIV-1 | |
| EP1369427A3 (en) | HIV-3 retrovirus strains and their use | |
| CA2140663A1 (en) | Compounds which inhibit hiv replication | |
| WO1999027958A3 (en) | Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination | |
| JP2003534016A5 (en) | ||
| CA2066053A1 (en) | Recombinant retroviruses delivering vector constructs to target cells | |
| KR940019314A (en) | Expression constructs, retroviral vectors containing human immunodeficiency bias (HIV) inhibitory antisense sequences and other nucleotide sequences, and recombinant retroviruses containing the same | |
| Dedera et al. | Conserved cysteine residues in the human immunodeficiency virus type 1 transmembrane envelope protein are essential for precursor envelope cleavage | |
| ES2140380T3 (en) | DNA SEQUENCES THAT CODE MODIFIED RETROVIRIC POLYPEPTIDES AND VACCINES THAT CONTAIN THEM OR ADDED THEREOF. | |
| RU2003128991A (en) | RECOMBINANT POXVIRUS CODING HIMERA IMMUNODEFICIENCY VIRUS CHEMICAL PROTEINS | |
| RU96116005A (en) | STRAIN HOMINIS IMMUNODEFICITI VIRUS (HIV-I) HIV-I / RUSSIA / GM-12-95 (RU1295) SUBTYPE B FOR DIAGNOSTIC AND VACCINE DRUGS | |
| WO1994006921B1 (en) | Recombinant retroviral vector against felv and/or fiv | |
| ES2683820T3 (en) | Use of non-subtype B GAG proteins for lentiviral encapsidation | |
| WO1997046697A3 (en) | Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections | |
| EP0465979B1 (en) | Anti HTLV-III (strain MN) monoclonal antibody | |
| AU630861B2 (en) | Recombinant hiv-2 polypeptides | |
| KR890009415A (en) | Antiviral compound and preparation method thereof | |
| CA2332623A1 (en) | Recombinant herpes viruses for preparing recombinant adeno-associated viruses | |
| WO2003029285A3 (en) | Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections | |
| AU8976691A (en) | Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof | |
| Hunsmann | Subunit vaccines against exogenous retroviruses: overview and perspectives | |
| WO2002069691A3 (en) | Immunogenic hiv peptides for use as reagents and vaccines | |
| WO1995024215A1 (en) | Retroviral vaccines, vaccination and immune-therapy for retroviral infections |